公司股东户数为4.36万户，前十大股东持股数量为5.50亿股，占总股本比例为54.16%，前十大股东持股 情况如下： 2025年7月30日，恩华药业(002262.SZ)发布2025年中报。 | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 徐州恩华投资有限公司 | 31.50% | | 2 | 孙彭生 | 4.89% | | 3 | 陈增良 | 3.93% | | 4 | 付咖 | 3.93% | | ર | 杨自亮 | 3.69% | | ଚ | 张旭 | 2.15% | | 7 | 马武生 | 1.22% | | 8 | 中国人寿保险股份有限公司-传统-普通保险产品-005L-CT001沪 | 1.11% | | 9 | 中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金 | 0.89% | | 10 | 全国社保基金四零六组合 | 0.84% | 公司营业总收入为30.10亿元。归母净利润为7.00亿元。经营活动现金净流入为4.95亿元，较去年同报告 期经营活动现金净流入减少1.27亿元，同比较去年同期下降20.43%。 公司摊薄每股收益为0. ...

Core Viewpoint - Enhua Pharmaceutical (002262.SZ) reported its semi-annual results for 2025, highlighting significant institutional investment and changes in public fund holdings [1][2]. Institutional Holdings - As of July 29, 2025, 22 institutional investors disclosed holdings in Enhua Pharmaceutical, totaling 374 million shares, which represents 36.83% of the company's total equity [1]. - The top ten institutional investors collectively hold 36.56% of the shares, with a slight increase of 0.09 percentage points compared to the previous quarter [1]. Public Fund Holdings - Three public funds reduced their holdings compared to the previous quarter, with a total decrease of 0.42% [2]. - Twelve new public funds disclosed holdings in Enhua Pharmaceutical, including notable names such as Southern CSI 500 ETF and Dachen Active Growth Mixed A [2]. - Fifteen public funds that previously held shares did not disclose their holdings this quarter, including several healthcare-focused funds [2]. Social Security Fund - One new social security fund, the National Social Security Fund 406 Combination, disclosed its holdings in Enhua Pharmaceutical during this period [2]. Insurance Capital - One insurance company, China Life Insurance Co., Ltd. - Traditional - Ordinary Insurance Product - 005L-CT001, increased its holdings by 0.2% compared to the previous period [2]. Foreign Investment - One foreign institution, Hong Kong Central Clearing Limited, did not disclose its holdings this quarter, indicating a potential shift in foreign investment interest [3].

丨 2025年7月30日星期三丨 NO.1诺和诺德下调全年财务指引 7月29日，诺和诺德美股盘前加速下跌，跌幅扩大至25%，此前公司下调2025年展望。公司预计2025年 在固定汇率下，全财年销售额增长8%~14%，此前预期增长13%~21%。这与Wegovy在美国肥胖市场的 增长预期较低，Ozempic在美国GLP-1糖尿病市场的增长预期较低，以及Wegovy在部分IO(国际运营)市 场的渗透率低于预期有关。 点评：诺和诺德下调全年业绩指引反映出GLP-1赛道从超预期增长向理性回归的趋势，也揭示出即便是 头部企业，在高基数和激烈市场竞争下亦难以持续高速扩张。Wegovy在肥胖适应证和Ozempic在糖尿病 领域的增长放缓，可能会影响整个GLP-1赛道的投资情绪，包括前期炒作激烈的国内相关原料药企业。 NO.2恩华药业（002262）：2025年上半年归母净利润约7亿元，同比增加11.38% 7月29日，恩华药业发布2025年半年报。报告期内，公司实现营业收入30.1亿元，同比增长8.93%；归属 于上市公司股东的净利润7亿元，同比增长11.38%。实现归属于上市公司股东的扣除非经常性损益的净 利润6.99亿 ...

Group 1 - Novo Nordisk has lowered its full-year financial guidance for 2025, expecting sales growth of 8% to 14% at constant exchange rates, down from a previous forecast of 13% to 21% [1] - The downward revision is attributed to lower growth expectations for Wegovy in the U.S. obesity market and Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration of Wegovy in certain international markets [1] - This adjustment reflects a trend of rational return in the GLP-1 sector, indicating that even leading companies face challenges in sustaining high-speed expansion amid high bases and intense market competition [1] Group 2 - Enhua Pharmaceutical reported a net profit of approximately 700 million yuan for the first half of 2025, an increase of 11.38% year-on-year, with total revenue reaching 3.01 billion yuan, up 8.93% [2] - The company's performance demonstrates steady growth in a challenging pharmaceutical industry, highlighting its solid market position in analgesics and psychiatric drugs [2] Group 3 - Changchun High-tech announced that its subsidiary has received FDA approval for the freeze-dried powder of Amlodipine Besylate oral solution, aimed at treating hypertension in children over 6 years old and adults with swallowing difficulties [3] - This product approval enhances the company's product portfolio in the U.S. market and strengthens its competitive position in the pharmaceutical sector [3] Group 4 - Zhixiang Jintai has received approval for clinical trials of its investigational product, Sluveimi Monoclonal Antibody Injection, for passive immunity in children and adolescents suspected of rabies virus exposure [4] - This product is the world's first dual-specific antibody for rabies passive immunity, indicating the company's innovative capabilities in developing biopharmaceuticals [4]

Core Insights - The company reported a continuous growth in operating performance for the first half of 2025, achieving a revenue of 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% from the previous year [2] - The company specializes in the research and production of central nervous system drugs, with 60 approved new drug formulations and a market share leading in 29 products nationwide [2] Financial Performance - Revenue for the first half of 2025 reached 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [2] - Net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [2] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase from the previous year [2] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of approximately 395 million yuan, representing a 23.97% increase year-on-year [2] - There are currently 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - The company has signed a Pre-A round preferred stock purchase agreement with San Sheng Pharmaceutical, gaining priority negotiation rights for certain in-development drugs [3] Collaborations and Partnerships - The company has entered into a commercial cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. for the market development of its Oxycodone tablets [3] - The NHL35700 drug, introduced from Denmark, has completed Phase II clinical trials and is set to enter Phase III trials [3] - The Protollin project, developed in collaboration with Harvard Medical School and Tianjing Biotech, has successfully completed Phase I clinical trials in the U.S. and is moving to Phase II trials [3]

Core Insights - The company reported a continuous growth in operating performance for the first half of 2025, with revenue reaching 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% year-on-year [1] - The company specializes in the research and production of central nervous system drugs, with 60 approved new drug formulations and a market share leading in 29 products nationwide [1] Financial Performance - Revenue for the first half of 2025 was 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [1] - Net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 699 million yuan, a 10.33% increase year-on-year [1] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of approximately 395 million yuan, which is a 23.97% increase compared to the previous year [1] - There are currently 17 innovative drug projects under development, including 1 completed Phase III clinical study and 2 completed Phase II studies [2] - The company has signed a Pre-A round preferred stock purchase agreement with San Sheng Pharmaceutical, gaining priority negotiation rights for some of its drug projects [2] Collaborations and Partnerships - The company has entered into a commercial cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. for the market development of its oxazepam tablet product [2] - The NHL35700 drug, introduced from Denmark, has completed Phase II clinical research and is about to enter Phase III [2] - The Protollin project, developed in collaboration with Harvard Medical School and Tianjing Biotechnology, has successfully completed Phase I clinical research in the U.S. and is set to enter Phase II [2]

Core Points - The supervisory board of Jiangsu Enhua Pharmaceutical Co., Ltd. has verified that the conditions for the first unlock period of the 2024 restricted stock incentive plan have been met [1] - A total of 750 individuals are eligible for the unlocking of 2,264,451 shares of restricted stock [1] - The board of directors will proceed with the necessary actions to unlock the shares in accordance with the authorization from the first extraordinary general meeting of shareholders in 2024 [1] Summary by Sections - **Verification of Conditions**: The supervisory board confirmed that neither the company nor the incentive recipients faced any restrictions preventing the unlocking of the restricted stock [1] - **Eligible Recipients**: The number of eligible recipients for the unlocking of restricted stock is 750, with a total of 2,264,451 shares available for unlocking [1] - **Board Approval Process**: The board of directors conducted the review of related proposals with associated directors abstaining from voting, ensuring compliance with relevant laws and regulations [1]

Group 1 - The supervisory board of Jiangsu Enhua Pharmaceutical Co., Ltd. held its third meeting of the seventh session on July 18, 2025, with all three supervisors present, confirming compliance with legal and regulatory requirements for the meeting [1] - The supervisory board reviewed and approved the procedures for the preparation and review of the company's 2025 semi-annual report, affirming that the report accurately reflects the company's financial status, operational results, corporate governance, business development, and major risks [1] - The supervisory board also approved the achievement of the first unlock condition for the restricted stock under the 2024 stock incentive plan, confirming that 750 eligible incentive recipients met the criteria for unlocking their restricted stocks [2]

*ST海华：控股子公司茫崖源鑫能源拟422.11万元收购若羌源鑫能源51%股权 每经记者｜陈晴 每经编辑｜程鹏 魏官红 并购重组 衢州发展：拟购买先导电科股份并募集配套资金 衢州发展公告，公司拟通过发行股份等方式购买广东先导稀材股份有限公司持有的先导电子科技股份有限公司的股份，同时募集配套资金。本次交易正在 筹划阶段，相关方案尚未最终确定。 *ST海华公告，控股子公司茫崖源鑫能源有限公司拟以现金422.11万元收购新疆庆源实业集团有限公司持有的若羌源鑫能源有限公司51%股权。本次交易 构成关联交易，但不构成重大资产重组。 中贝通信：终止控股子公司贝通信国际股权收购事项 中贝通信公告，公司控股子公司贝通信国际计划以自有资金2500万美元（折合人民币约1.82亿元）收购PT.Semesta Energi Services 55%股权，但因未满足 投资协议中约定的核心交割条件，经协商决定终止本次收购事宜。此次终止不会对公司现有经营业绩及财务状况产生不利影响。 业绩披露 仕佳光子：2025年上半年归属于上市公司股东的净利润2.17亿元，同比增长1712% 仕佳光子公告，2025年上半年营业收入9.93亿元，同比增长1 ...

分组1 - Shijia Photon reported a revenue of 993 million yuan for the first half of the year, a year-on-year increase of 121.12% [1] - The net profit attributable to shareholders reached 217 million yuan, reflecting a significant year-on-year growth of 1712% [1] - The company has successfully developed new products for data centers and AI computing, including high-power CWDFB lasers and high-temperature FAU devices [1] 分组2 - Hunan Tianyan announced that China Changan Automobile has become its indirect controlling shareholder after a division of the Weaponry Equipment Group [2] - Following the division, China Changan Automobile holds 37.25% of Hunan Tianyan through Chen Zhi Group, maintaining the actual controller as the State-owned Assets Supervision and Administration Commission [2] 分组3 - Dong'an Power stated that its indirect controlling shareholder has changed to China Changan Automobile after the division of the Weaponry Equipment Group [2] - China Changan Automobile now holds 50.93% of Dong'an Power's total shares through Chen Zhi Group [2] 分组4 - Wantong Intelligent signed an exclusive authorization agreement with Shanghai Shenming Aosi Semiconductor Technology, allowing it to produce and sell boards based on the Fellow 1 model chip for five years [3] - This collaboration is expected to positively impact the company's future operations and aligns with its long-term development strategy [3] 分组5 - WuXi AppTec plans to adjust the upper limit for its share repurchase price from 90.72 yuan to 114.15 yuan per share [4] 分组6 - Xinya Electronics reported that the revenue from high-frequency and high-speed copper cable connectors accounted for only 3.31% of its total revenue as of the 2024 annual report [5] - The company experienced abnormal stock trading fluctuations with a cumulative price deviation exceeding 20% over three consecutive trading days [5] 分组7 - Huajin Technology plans to acquire 6% of Crystal Integrated's shares for a total price of 2.393 billion yuan, with a transfer price of 19.88 yuan per share [6] - This transaction does not constitute a related party transaction or a major asset restructuring [6] 分组8 - Fangbang Co. reported that the sales revenue from its peelable copper products accounted for less than 0.3% of its main business revenue in the first half of the year [8] - The company is monitoring potential market demand increases due to the adoption of CoWoP technology by leading overseas companies [8]